GDRX Q3 2025 Earnings Call Summary

Total Revenue: $196 million, a slight increase of approximately $1 million year-over-year.
Prescription Transaction Revenue: Down 9% year-over-year, primarily due to Rite Aid store closures and lower transaction volume in an integrated savings program.
Manufacturer Solutions Revenue: $43.4 million, representing a strong year-over-year growth of 54%.
Adjusted EBITDA: $66.3 million, a 2% increase year-over-year, with an adjusted EBITDA margin of 33.8%.
Cash Position: $273.5 million in cash on hand, with $80 million available under the revolving credit facility.
Share Repurchase: Approximately 13.4 million shares repurchased at an average price of $4.61, totaling $61.6 million.

Expanded partnerships with pharmaceutical manufacturers, including Novo Nordisk and Amgen, to offer direct-to-consumer cash pricing for select medications.
Launched the RxSmartSaver counter solution at Kroger pharmacies, enhancing affordability programs.
Introduced the "Savings Wrangler" brand campaign to reinforce GoodRx's position as a trusted name in prescription savings.
Continued investment in e-commerce capabilities and subscription offerings, including new services for hair loss and weight loss treatments.
Strong focus on integrating with the evolving pharmacy ecosystem and engaging with government initiatives like TrumpRx to enhance pricing transparency.

Full-year revenue guidance remains unchanged, expected to exceed $792 million.
Anticipated sequential revenue decline in Q4 due to the earlier closing of manufacturer solutions deals.
Adjusted EBITDA projections for the full year remain unchanged, with expected growth of 2% to 6% compared to 2024.
Manufacturer Solutions revenue projected to grow approximately 35% for the full year.

Declining Prescription Transaction Revenue: The 9% decline is attributed to Rite Aid closures and reduced transaction volume, impacting monthly active consumers.
Market Headwinds: Ongoing uncertainty in the healthcare landscape, including potential changes to insurance coverage and rising out-of-pocket costs for consumers.
Competitive Pressures: Increased competition from other affordability programs and evolving PBM models that may affect GoodRx's market share.

Management acknowledged the challenges posed by Rite Aid closures and emphasized efforts to recapture displaced users.
Discussion on the evolving PBM landscape, with a focus on the shift from rebate models to point-of-sale discounts, which aligns with GoodRx's mission.
Insights into the Manufacturer Solutions segment indicated that while there may be quarterly variability, the overall trend is expected to be upward.
Management expressed confidence in their strategic positioning to leverage upcoming regulatory changes and market dynamics to drive growth in 2026 and beyond.

GDRX — GoodRx Holdings, Inc.